New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 21, 2014
11:23 EDTECYTEndocyte price target raised to $41 from $21 at Brean Capital
Brean Capital raised its price target for Endocyte shares to $41 following the positive CHMP positive decision for vintafolide and the positive Phase 2 trial results. The firm keeps a Buy rating on the stock.
News For ECYT From The Last 14 Days
Check below for free stories on ECYT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 8, 2014
05:30 EDTECYTEndocyte assumed with a Buy at Brean Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use